{"url":"https://newsforagent.com/news/2026-11-12/pai-pharma-acquires-nexus-pharmaceuticals","markdown_url":"https://newsforagent.com/news/2026-11-12/pai-pharma-acquires-nexus-pharmaceuticals.md","title":"PAI Pharma Acquires Nexus Pharmaceuticals","headline":"PAI Pharma Acquires Nexus Pharmaceuticals to Expand Hospital Injectable Portfolio","description":"PAI Pharma acquired Nexus Pharmaceuticals, adding more than 20 hospital injectable products to its sterile injectable portfolio and expanding its hospital reach.","section":"Mergers & Acquisitions","published_at":"2026-11-12T18:19:23+00:00","modified_at":"2026-11-12T18:19:23+00:00","author":"News Desk","key_takeaways":["PAI Pharma acquired Nexus Pharmaceuticals, a specialty company focused on complex injectable medicines for critical care and oncology.","Nexus brings an established commercial portfolio of more than 20 hospital injectable products to PAI.","William Blair served as exclusive advisor and Kirkland & Ellis LLP as legal counsel to PAI Pharma on the transaction."],"companies":[{"name":"PAI Pharma","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0006n3y/pai-pharma","website":"http://paipharma.com"},{"name":"Nexus Pharmaceuticals","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0005vyn/nexus-pharmaceuticals","website":"https://www.nexuspharma.net"}],"source":{"publisher":"PR Newswire","title":"PAI Pharma Acquires Nexus Pharmaceuticals, Expanding Portfolio of Sterile Injectable Products","url":"https://www.prnewswire.com/news-releases/pai-pharma-acquires-nexus-pharmaceuticals-expanding-portfolio-of-sterile-injectable-products-302937821.html"},"other_sources":[],"tags":["Mergers & Acquisitions","PAI Pharma","Nexus Pharmaceuticals"],"body_markdown":"[PAI Pharma](https://akta.pro/company-profiles/0006n3y/pai-pharma) acquired [Nexus Pharmaceuticals](https://akta.pro/company-profiles/0005vyn/nexus-pharmaceuticals), a specialty pharmaceutical company focused on complex injectable medicines, the company said on November 12, 2026. [PR Newswire](https://www.prnewswire.com/news-releases/pai-pharma-acquires-nexus-pharmaceuticals-expanding-portfolio-of-sterile-injectable-products-302937821.html) carried the announcement. PAI Pharma is a U.S. developer, manufacturer and marketer of oral liquid medicines and ready-to-use sterile injectable and hospital-focused products, and a portfolio company of Olympus Partners. Nexus Pharmaceuticals develops and commercializes injectable medicines used in critical care, oncology and other hospital settings.\n\n## PAI Pharma's Acquisition of Nexus Pharmaceuticals\n\nNexus brings an established commercial portfolio of more than 20 hospital injectable products, deep customer relationships and expertise in developing and commercializing critical therapies, according to the announcement. PAI said the acquisition marks another step in its strategy to build a broader portfolio of essential medicines and expand its presence in the hospital and sterile injectable markets.\n\nThe combined business pairs PAI's leadership in ready-to-dose oral liquid medicines and its growing sterile injectable business with Nexus's hospital injectable portfolio. PAI's sterile injectable business includes the recent acquisition of Nivagen and its aseptic manufacturing capabilities in Sacramento. PAI said the Nexus acquisition strengthens its ability to serve hospitals and healthcare providers with a broader range of pharmaceutical products.\n\nWilliam Blair acted as exclusive advisor to PAI Pharma, and Kirkland & Ellis LLP acted as legal counsel. Proskauer Rose LLP acted as legal counsel to Nexus Pharmaceuticals. The announcement did not state a purchase price or expected closing date.\n\n## PAI Pharma's Recent Deal History\n\nPAI Pharma acquired Nivagen Pharmaceuticals in January 2026, adding a Sacramento aseptic facility and more than 20 ready-to-use sterile injectable products, according to akta.pro [company records](https://akta.pro/company-data). The same records describe a combined pipeline of approximately 30 sterile products from that deal. Olympus Partners acquired PAI Pharma as a portfolio company in February 2025, providing private equity capital from a firm managing over $12 billion to support continued acquisitions and growth in oral liquids and sterile injectables, the same records show. PAI Pharma's products are distributed through major wholesalers including AmerisourceBergen, Cardinal Health and Cencora, according to the same records.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}